Literature DB >> 29297125

Cross-reactivity of antigens and antibodies belonging to different pathogenic types of human papillomaviruses.

R K Salyaev1, N I Rekoslavskaya2,3, A S Stolbikov2,4.   

Abstract

The analysis of the properties of a quadrivalent peroral vaccine against the cervical cancer, which was created in a plant expression system on the base of transgenic tomato fruits, by immunoassay and Western blot hybridization showed that the antibodies against human papilloma virus 16 L1 (HPV16 L1) actively interacted not only with the antigenic proteins HPV18 L1, HPV31 L1, and HPV45 L1, but also with the antigenic protein HPV6 L1, which belongs to another HPV family. Thus, new data on the possibility of crossreactivity between antibodies and antigens belonging to remote HPV families were obtained.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29297125     DOI： 10.1134/S1607672917060084

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  11 in total

Review 1.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

2.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Authors:  Darron R Brown; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Eng Hseon Tay; Patricía Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret James; Teresa M Hesley; Eliav Barr
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

3.  Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

Authors:  Lars Toft; Martin Tolstrup; Martin Müller; Peter Sehr; Jesper Bonde; Merete Storgaard; Lars Østergaard; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

4.  Reduced effectiveness of CD4+Foxp3+ regulatory T cells in CD28-deficient NOD.H-2h4 mice leads to increased severity of spontaneous autoimmune thyroiditis.

Authors:  Jason S Ellis; So-Hee Hong; Habib Zaghouani; Helen Braley-Mullen
Journal:  J Immunol       Date:  2013-10-04       Impact factor: 5.422

5.  An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.

Authors:  Aldo Venuti; Silvia Massa; Vadim Mett; Laura Dalla Vedova; Francesca Paolini; Rosella Franconi; Vidadi Yusibov
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

6.  Anti-cancer activity of plant-produced HPV16 E7 vaccine.

Authors:  Silvia Massa; Rosella Franconi; Rossella Brandi; Antonio Muller; Vadim Mett; Vidadi Yusibov; Aldo Venuti
Journal:  Vaccine       Date:  2007-01-19       Impact factor: 3.641

7.  Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).

Authors:  Troy J Kemp; Mahboobeh Safaeian; Allan Hildesheim; Yuanji Pan; Kerri J Penrose; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
Journal:  Vaccine       Date:  2012-10-31       Impact factor: 3.641

8.  Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

9.  Disassembly activity of actin-depolymerizing factor (ADF) is associated with distinct cellular processes in apicomplexan parasites.

Authors:  Silvia Haase; Dennis Zimmermann; Maya A Olshina; Mark Wilkinson; Fabio Fisher; Yan Hong Tan; Rebecca J Stewart; Christopher J Tonkin; Wilson Wong; David R Kovar; Jake Baum
Journal:  Mol Biol Cell       Date:  2015-07-08       Impact factor: 4.138

10.  Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Authors:  Sara L Bissett; Eve Draper; Richard E Myers; Anna Godi; Simon Beddows
Journal:  Vaccine       Date:  2014-01-15       Impact factor: 3.641
View more
  1 in total

Review 1.  Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

Authors:  Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.